Dr Mahadev Rao
Professor
Date of Joining: 03.04.2017
Department of Pharmacy Practice
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
- Approved PhD guide (Field:Cancer/ TB) in 沙巴体育 Academy of Higher Education.
- Supervises the department's daily activities.
- Mentors student's disserations and projects.
- Plans and conducts clinical pharmacy workshops and training programs.
- Establishes research collaborations at national and international levels.
- Member of Pharmacy and Therapeutic Committee of Kasturba Hospital, 沙巴体育.
- Member of Institutional Ethics Committee (IEC) of KMC&KH
- Heads research committee of the department.
- Coordinator of? Global TB Portal Consortium of the National Institute of Health (NIH), USA in India
- Founding faculty of Global Cancer Consortium
- Coordinator of Centre for Translational 沙巴体育
- Coordinator of Certificate Course in Translational 沙巴体育
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
Mahadev Rao, Professor and Head at Department of Pharmacy Practice, 沙巴体育 College of Pharmaceutical Sciences, joined 沙巴体育 Academy of Higher Education on April 04, 2017. Dr. Rao completed his PhD in pharmaceutical sciences at 沙巴体育 College of Pharmaceutical Sciences, studying free radical-induced nephrotoxicity of cisplatin and its protection by selenium compounds. His PhD research work won him the Simon Wolf Charitable Foundation award (Cambridge, UK) in 1998. Determined to pursue a career in research, Mahadev moved to National Cancer Institute, NIH, Bethesda, MD as a Fogarty 沙巴体育 Postdoctoral Fellow where he worked for two years in basic cancer genetics. In 2003, Dr Rao moved to Lombardi Cancer Center, Georgetown University to purse signal transduction mechanisms of cyclins in breast and prostate cancer. In 2006, Dr. Rao joined Surgery/thoracic gastro-intestinal branch at NCI where he rose from a position of Postdoctoral Scientist to that of a Staff Scientist at National Cancer Institute. Dr. Rao has worked extensively on basic, translational and clinical research at NCI. His major expertise include repurposing? old antitumor agents, personalized medicine in thoracic cancers (lung, malignant pleural mesothelioma, esophageal and gastric), genetic mechanisms for tobacco mediated cancers, induction of cancer testis antigens in thoracic cancer by epigenetic drugs for adoptive immunotherapy and the metabolome. Dr. Rao has numerous papers in peer reviewed journals such as Nature, Nature immunology, Cancer 沙巴体育, Clinical Cancer 沙巴体育, Journal of immunology, Journal of immunotherapy, Molecular Cell, MCB, JBC, PNAS, Cell metabolism, Cell cycle, Molecular Cancer, etc.?
He teaches undergraduate and postgraduate students; and guide doctoral students.
He:
?
SUBJECTS CURRENTLY TEACHING
| Subject | Semester / Year |
|---|---|
| Pharmacotherapeutics-III | Fourth Year Pharm.D |
| Pharmacotherapeutics- I & II | First Year Pharm.D (PB) |
| Clinical 沙巴体育 | Fifth Year Pharm.D |
| Pharmacotherapeutics-I | First Semester M.Pharm |
| Clinical 沙巴体育 | First Semester M.Pharm |
| Pharmacotherapeutics-II | Second Semester M.Pharm |
ACADEMIC QUALIFICATIONS
| Degree | Specialisation | Institute | Year of passing |
|---|---|---|---|
| PhD (Doctor of Philosophy) | Pharmaceutical Sciences | 沙巴体育 College of Pharmaceutical Sciences / Mangalore University | 2000 |
| MPharm (Master of Pharmacy) | Pharmacology | Government College of Pharmacy, Bangalore University, Bangalore | 1995 |
| BPharm (Bachelor of Pharmacy) | Pharmacy | NGSM Institute of Pharmaceutical Sciences, Mangalore University, Mangalore | 1992 |
| DPharm (Diploma of Pharmacy) | Pharmacy | SSS College of Pharmacy, Kadandale | 1986 |
Experience
| Institution / Organisation | Designation | Role | Tenure |
|---|---|---|---|
| Department of Pharmacy Practice, MCOPS, 沙巴体育 | Professor & Head | Teaching & 沙巴体育 | 2017-onwards |
| Surgery/Thoracic and GI Oncology Branch, NCI/NIH, Bethesda, MD | Staff Scientist | 沙巴体育 | 2012-2016 |
| Surgery Branch, NCI/NIH, Bethesda, MD | 沙巴体育 fellow | 沙巴体育 | 2007-2012 |
| Department of Oncology, Georgetown University, Washington DC | Postdoc Fellow | 沙巴体育 | 2003-2007 |
| Division of Basic Sciences, NIH, Bethesda, MD | Forgaty 沙巴体育 Postdoc Fellow | 沙巴体育 | 2000-2002 |
| NGSM Institute of Pharmaceutical Sciences, Mangalore, India | Assistant Professor & Head, Dept. of Pharmacology | Teaching UG and PG students and 沙巴体育 | 1999-2000 |
Sixteen years research experience in government research laboratories.
Dr Mahadev Rao
Major areas of expertise are preclinical and clinical cancer biology and immunology, epigenetics, human iPSCs, molecular biology and signal transduction.
Dr Mahadev Rao
Developed epigenetic drugs as antitumor agents for lung, malignant mesothelioma cancer therapy.
Dr Mahadev Rao
Managed independent line of research in oncology, chemotherapy, immunotherapy, cancer progression, drug discovery and development, cancer biomarkers, and epigenetics.
Dr Mahadev Rao
Oversee/ Coordinated/ Developed Therapeutic vaccine development against thoracic cancers.
Dr Mahadev Rao
Guided, designed, developed and implemented strategies to evaluate PK/PD.
Dr Mahadev Rao
Managed three of the FDA approved clinical trials as associate investigator in Phase I and Phase II.
Dr Mahadev Rao
Responsible for development of novel epigenetic drugs for its antitumor activity against thoracic cancers.
Dr Mahadev Rao
Lead translational oncology projects that generated proof-of-concept for novel therapeutic strategies from drug discovery to preclinical animal models.
Dr Mahadev Rao
Discovered tobacco mediated carcinogen effects in lung cancers and its epigenetic mechanism.
Dr Mahadev Rao
Managed multicenter teams for pre-clinical studies on tobacco induced carcinogenesis, oncogenes, tumor suppressor genes, and novel epigenetic small molecule inhibitors.
Dr Mahadev Rao
Developed human iPSCs from Small Airway Epithelial Cells.
Dr Mahadev Rao
Authored 51 publications in top international scientific journals (notably Nature, Nature Immunology, Cell Metabolism, Cell Stem Cell, Molecular Cell, Cancer 沙巴体育, PNAS and Clinical Cancer 沙巴体育) 45 presentations at international scientific meetings.
Dr Mahadev Rao
Peer-reviewed research articles for Anticancer 沙巴体育, Cancer 沙巴体育, Carcinogenesis, Clinical epigenetics and inflammation.
Dr Mahadev Rao
Strong record of building successful collaborative relationships with industry key scientific researchers and opinion leaders.
Dr Mahadev Rao
Experience in supervising 12 clinical surgeons to obtain training in thoracic oncology.
Dr Mahadev Rao
Experience in translational, clinical and basic research (signal transduction, genetics, molecular biology and epigenetics (RNAseq, ChIP-seq, MeDIPseq, DNA methylation etc).
Dr Mahadev Rao
Coordinated interactions between NIH and outside organizations including foundations, biotechnology and pharmaceutical firms, academic institutions, and a host of government and non-government agencies.
Dr Mahadev Rao
Created and implemented strategies and tactics to find funds to magnify the impact of the program and optimize and leverage all available resources.
Dr Mahadev Rao
Ensure lab compliance with NIH-mandated safety requirements and procedures – coordinate with NIH Office of Safety on violations and associated corrective actions.
Dr Mahadev Rao
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Interest
Developing tumor tissue collection bank from various histologies as well as will generate in-house tumor cell lines and eventually those tumor samples will be subjected to exome or transcriptome profiling. Generation of this genomic databank at 沙巴体育 University will be used for intramural as well as extramural prospective studies, basic, translational and clinical research. Also Dr Rao would like to establish the repurposing old anticancer drugs as well as to establish the personalized treatment of cancers based on genetic makeup in 沙巴体育 University.
Area of Expertise
Repurposing old antitumor agents, personalized medicine in thoracic cancers (lung, malignant pleural mesothelioma, esophageal and gastric), genetic mechanisms for tobacco mediated cancers, induction of cancer testis antigens in thoracic cancer by epigenetic drugs for adoptive immunotherapy and the metabolome. Dr. Rao had involved in several preclinical and FDA approved clinical trials in repurposing the old drugs and in personalized lung cancer and mesothelioma patients.
Area of 沙巴体育
Discovery and development of anti-cancer drugs that exploit our knowledge of the cancer genome and cancer biology. His passion is personalized medicine and repurposing of old drugs.
Professional Affiliations & Contributions
- Member of American Association for Cancer 沙巴体育
- Member of Registered Pharmacist, Karnataka State Pharmacy Council
- Life Member of Indian Pharmaceutical Association
HONORS/AWARDS:
- Department of Human & Health Services best employee performance award from 2008-2015
- Fogarty 沙巴体育 postdoctoral fellowship award at NIH (2000-2002)
- Simon Wolf Charitable foundation award (Cambridge, UK) for contribution in Free Radical Biology
- Senior 沙巴体育 Fellowship for Ph.D. from Department of Atomic Energy, India
- Junior 沙巴体育 Fellowship for M.Pharm. from University Grants Commission, India
COLLABORATIONS:
- Dr. Narayanan Rajendran, University of Kentucky, USA
- Dr. Ganesha Rai Bantukallu, NCATS, NIH, Shadygrove, USA
- Dr. Vivek Shukla, TGBI, NCI, NIH, Bethesda, USA
OTHER ASSOCIATIONS:
- Member of Pharmacy and Therapeutic Committee of Kasturba Hospital, 沙巴体育
Full Publications list
Dr Mahadev Rao
Tobacco smoke induces polycomb- mediated repression of DKK1 in lung cancer cells
Hussain M Rao M Humphries A et al
Cancer 沙巴体育, 2009 Apr 15;69(8):3570-8
Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate
Liu F Killian JK Yang M et al
Oncogene, 2010; 29(25):3650-64
A TCR targeting the HLA- A*0201-restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer
Chinnasamy S Wargo JA Yu Z et al
Journal of Immunology,2011;186(2):685-696
Inhibition of Histone Lysine Methylation Facilitates De-repression of Cancer-Testis Genes in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer.
Rao M Chinnasamy S Hong JA et al
Cancer 沙巴体育, 2011; 71(12):4192-4204
Cigarette Smoke Induces Expression of the Putative Stem Cell Marker ABCG2 in Cultured Esophageal Adenocarcinoma Cells
Zhang M Mathur A Zhang Y et al
Cancer 沙巴体育, 2012 Aug 15;72(16):4178-4192
Depletion of Polycomb Repressor Complex-2 Inhibits the Malignant Phenotype of Pleural Mesothelioma Cells in vitro and in vivo
Kemp CD Rao M Hong JA et al
Clinical Cancer 沙巴体育, 2012 Jan 1;18(1):77-90
Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice
Portal S Shankavaram U Rao M et al
Cancer 沙巴体育, 2012 Nov 15;72(22):5790-5800.
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice
Peer CJ Rao M et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:142-6
MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells
Xie Y Tobin LA Camps J et al
Oncogene, 2013 May 9;32(19):2442-51
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis
Roychoudhuri R Hirahara K Mousavi K et al
Nature, 2013 Jun 27;498(7455):506-10
Frequency and Potential Clinical Relevance of Telomerase Complex Mutations in Esophageal Cancer
Zhang Y Calado R Cabrera-Pérez J et al
PLoS One, 2014 Jul 1;9(7):e101010
A Novel Murine T Cell Receptor Targeting NY- ESO-1
Rosati SF Parkhurst M Hong Y et al
Journal of Immunotherapy, 2014 Apr; 37(3):135-46
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Rao M Atay S Shukla V et al
Clinical Cancer 沙巴体育, 2016 Mar 1;22(5):1197-210
Metabolic-sorting of cells with enhanced stem-like properties for cell therapy
Sukumar M Liu J Mehta GU et al
Cell Metabolism, 2016 Jan 12; 23(1):63-76